

pCODR Information Session for Pharmaceutical Manufacturers

August 23, 2011

Hello,

The pan-Canadian Oncology Drug Review (pCODR) is a newly established evidence-based cancer drug review process, designed to bring consistency and clarity to the assessment of cancer drugs by looking at clinical evidence, cost-effectiveness and patient perspectives. The information that results from this process will be used to provide evidence-based recommendations to provinces and territories to guide their drug funding decisions.

We are inviting pharmaceutical manufacturers and consultants to attend an information session on the pCODR Review Process on **September 22, 2011** at the **Best Western Hotel, 5825 Dixie Road in Mississauga**, from 10:00 a.m. to noon in the Sunset Hall meeting room.

The objectives of the session are to:

1. provide an overview of the pCODR process
2. review manufacturer participation during the review process
3. highlight key steps in preparing a submission for pCODR review

Please confirm your attendance at the information session via e-mail: rsvp@pcodr.ca by September 19, 2011. There are a limited number of spaces available for this information session; each organization will be allowed up to 3 participants to accommodate interest. Please note that if you are unable to attend pCODR will be offering future webinars to cover the same material.

We hope you will be able to join us at this information session. The contributions of pharmaceutical manufacturers have been invaluable in shaping the pCODR process.